

Lessons Learned From The Nellix Experience: Why Sac Sealing Should Still Be Pursued For EVAR, But Not From The Nellix Platform: What Changes Would Make Sac Sealing Devices Work

Matt Thompson, MD., FRCS. President and CEO Endologix LLC, Irvine, CA

NOVEMBER 2024









EVAS 2 IDE 2 Year Results		
Outcome	60 months	
Freedom from:		
Type IA endoleak	95.3%	
Type II endoleak	95.3%	
Type III endoleak	100%	
Migration	97.3%	
Graft occlusion	96.8%	 Primary safety and efficacy end points means
Secondary interventions		
		 Applicability low due to constrained IFU
		(<20% all AAA)
All Cause mortality		

















Concluding Remarks

- EVAS / Nellix was a new therapy not a new EVAR product:
- Significant implications for launch metrics and outcome reporting
 Active management of aneurysm sac with Nellix demonstrated positive findings
- Active sac management should conform to principles that have been
 successful in EVAR separation of function (fixation, seal, sac management)
 - o Ability to replicate these with proposed adjunctive therapies to current endografts? Lifeseal Vascular / Shape Memory
- c with Nellix demonstrated positive form to principles that have been unction (fixation, seal, sac management)